ImmunoPrecise, NIH, Integrated Biotherapeutics test antibodies for COVID-19

By The Science Advisory Board staff writers

June 4, 2020 -- ImmunoPrecise Antibodies announced that it is collaborating with the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health (NIH) and Integrated Biotherapeutics to study molecular binding interactions of therapeutic antibody candidates for COVID-19.

The research consortium will characterize lead antibodies using cyrogenic electron microscopy (cryo-EM) to determine structural details of antibodies bound to the spike protein from SARS-CoV-2. Integrated Biotherapeutics will provide the trimeric spike protein ectodomain and receptor binding domain against which ImmunoPrecise's antibodies will be studied. The data will shed light on how ImmunoPrecise's lead candidate antibodies neutralize the virus.

Copyright © 2020
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here